Evidence map›Paper›PMID 34395253›Full record

ArticleFrontiers in oncology2021

Cancer Cells Can Exhibit a Sparing FLASH Effect at Low Doses Under Normoxic

Gabriel Adrian, Elise Konradsson, Sarah Beyer, Anders Wittrup, Karl T Butterworth, Stephen J McMahon, Mihaela Ghita, Kristoffer Petersson, Crister Ceberg

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Gabriel AdrianDivision of Oncology and Pathology, Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Elise KonradssonDepartment of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.
Sarah BeyerDivision of Oncology and Pathology, Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Anders WittrupDivision of Oncology and Pathology, Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden.
Karl T ButterworthPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
Stephen J McMahonPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
Mihaela GhitaPatrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
Kristoffer PeterssonDepartment of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden.
Crister CebergDepartment of Medical Radiation Physics, Clinical Sciences, Lund University, Lund, Sweden.
Lund University · SEQueen's University Belfast · GBSkåne University Hospital · SEMedical Research Council · GB

Funding

Medical Research Council MC_UU_00001/9
6 · The paper itself

Abstract

backgroundIrradiation with ultra-high dose rate (FLASH) has been shown to spare normal tissue without hampering tumor control in several

methodsSeven cancer cell lines (MDA-MB-231, MCF7, WiDr, LU-HNSCC4, HeLa [early passage and subclone]) and normal lung fibroblasts (MRC-5) were irradiated with doses ranging from 0 to 12 Gy using FLASH (≥800 Gy/s) or conventional dose rates (CONV, 14 Gy/min), with a 10 MeV electron beam from a clinical linear accelerator. Surviving fraction (SF) was determined with clonogenic assays. Three cell lines were further studied for radiation-induced DNA-damage foci using a 53BP1-marker and for cell cycle synchronization after irradiation.

resultsA tendency of increased survival following FLASH compared with CONV was suggested for all cell lines, with significant differences for 4/7 cell lines. The magnitude of the FLASH-sparing expressed as a dose-modifying factor at SF=0.1 was around 1.1 for 6/7 cell lines and around 1.3 for the HeLa

conclusionWe have found a FLASH effect appearing at low doses under normoxic conditions for several cell lines

Indexed as

cancer cell linesclonogenic assayFLASHnormoxiaradiobiologyradioresistanceradiotherapyultra-high dose rate irradiation

Identifiers

PMID34395253
PMCPMC8358772
OpenAlexW3186042081

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.